Evidence map›Paper›PMID 42707485›Full record

ReviewFrontiers in bioengineering and biotechnology2026

Gene therapy for genodermatoses at the crossroads of innovation and clinical translation.

Alessandra Fabrizi, Marta Valenti, Silvia Zacchino, Katia Russo, Erica Baschetti, Laura De Rosa, Michele De Luca

Abstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alessandra Fabrizi *Centre for Regenerative Medicine "Stefano Ferrari" Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Marta Valenti *Centre for Regenerative Medicine "Stefano Ferrari" Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Silvia Zacchino *Centre for Regenerative Medicine "Stefano Ferrari" Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Katia Russo *Centre for Regenerative Medicine "Stefano Ferrari" Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Erica Baschetti *Centre for Regenerative Medicine "Stefano Ferrari" Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Laura De RosaCentre for Regenerative Medicine "Stefano Ferrari" Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Michele De LucaCentre for Regenerative Medicine "Stefano Ferrari" Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inherited genodermatoses are a heterogeneous group of rare monogenic disorders. Among these, epidermolysis bullosa (EB) and ichthyoses represent paradigmatic disorders characterized by severe skin fragility and hyperkeratosis, respectively, and impaired barrier function, often with profound effects on quality of life and systemic health. Current management remains largely palliative, underscoring the urgent need for disease-modifying therapies. Over the past 2 decades, advances in epithelial stem cell biology, vector engineering and genome editing technologies have transformed the therapeutic landscape for genodermatoses.

Indexed as

epidermolysis bullosa (EB)gene editinggene therapygenodermatosesichthyosisregenerative medicinestem cells

Identifiers

PMID42707485
PMCPMC13547483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.